Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30298614 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL160878 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL30940600 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL3229637 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL7256052 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL27995840 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL2770263 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL2769195 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL2768908 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HTR2BABCB11NR3C1 | |
| SCHEMBL29662014 | 0.78 | CYP3A4 (0.54) | ALDH1A1CYP3A4HTR2BHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115411362-A | Electrolyte for lithium ion battery, lithium ion battery and preparation method thereof | 江苏海四达电源有限公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2022211574-A1 | COMPOSITION FOR PREVENTING OR TREATING CHRONIC KIDNEY DISEASE, COMPRISING COMPOUND THAT INDUCES EXPRESSION OF ANTI-AGING GENE KLOTHO | 주식회사 클로소사이언스 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022211420-A1 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE COMPRISING COMPOUND INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO | 주식회사 클로소사이언스 | 2022-10-06 | — | — | WO | disclosed |
| CN-109476696-B | Anti-trypanosome and anti-leishmania agents for animals and humans | 细胞基因公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021066608-A1 | COMPOUND FOR INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO AND USE THEREOF | 주식회사 클로소사이언스 | 2021-04-08 | — | — | WO | disclosed |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| WO-2006043121-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-27 | — | — | WO | disclosed |
| EP-1272175-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040253636-A1 | Method of protein analysis | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1430307-A2 | A METHOD OF PROTEIN ANALYSIS | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-06-23 | — | — | EP | disclosed |
| US-6680317-B2 | N-(PHENYL)-N*-(2-HYDROXY-3-AMINOSULFONYLPHENYL)GUANIDINE DERIVATIVES; CHEMOKINE INHIBITORS; RESPIRATORY, CARDIOVASCULAR, RHEUMATIC, BRAIN, AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030216375-A1 | Il-8 receptor anatagonists | GLAXOSMITHKLINE LLC | 2003-11-20 | — | — | US | disclosed |
| CN-1452483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-10-29 | — | — | CN | disclosed |
| WO-2003027681-A2 | A METHOD OF PROTEIN ANALYSIS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-04-03 | — | — | WO | disclosed |
| EP-1272175-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001072960-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | ALDH1A1 749/4885CYP3A4 2675/4885HTR2B 3198/4885 |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | ALDH1A1 749/4885CYP3A4 2675/4885HTR2B 3198/4885 |
| US-20030216375-A1 | Il-8 receptor anatagonists | CXCL8, CCR8, IL1R1 | ALDH1A1 1275/4885CYP3A4 1758/4885HTR2B 2408/4885 |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | ALDH1A1 749/4885CYP3A4 2675/4885HTR2B 3198/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | ALDH1A1 749/4885CYP3A4 2675/4885HTR2B 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.